What are Clinical Trials

Similar documents
New Developments in Cancer Treatment. Dulcinea Quintana, MD

New Developments in Cancer Treatment. Ian Rabinowitz MD

Genomics Up Close And Personal: What Are The Implications For Cancer Nursing? Candy Cooley Head of Education

INTRODUCTION TO FOX TRIAL FINDER. Accelerating Clinical Trial Recruitment Online

Targeted Medicine and Molecular Therapeutics. Angus McIntyre, M.D. Medical Oncologist, Addison Gilbert Hospital and Beverly Hospital October 6, 2009

American Cancer Society Research Programs

Bevacizumab is currently licensed for the following indication relevant for this NICE review:

Objectives. Briefly summarize the current state of colorectal cancer

Jules Bordet Institute, Brussels, Belgium Université Libre de Bruxelles Breast International Group (BIG aisbl), Chair ESMO President

MEDCHEM 562. Second Midterm. November 9, 2012

Media Release. Basel, 07 December 2017

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

Media Release. Basel, 26 March 2018

ULTIMATE GBG 95 UC-0140/1606 BIG UnLock The IMmune cells ATtraction in ER+ breast cancer

CANCER 1.7 M 609,000 26% 15.5 M 73% JUST THE FACTS. More Than 1,100 Cancer Treatments in Clinical Testing Offer Hope to Patients

Cancer. October is National Breast Cancer Awareness Month

Media Release. Basel, 7 May 2018

College of the Canyons Fall 2009 Scholarly Presentation by Kelly J. Cude, Ph.D.

Outline of the presentation

Breast Cancer & Personalized Medicine

Proposing Trastuzumab as an Essential Medicine to Treat Cancer: Insight on Methodologies, Processes and Outcomes. Lorenzo Moja

PTAC meeting held on 5 & 6 May (minutes for web publishing)

Backgrounder. 1. What are targeted therapies? 2. How do targeted therapies work?

Formation Biologics. A clinical-stage biopharmaceutical company Lead program projected to achieve clinical validation in 2018

Drug-targeted therapies and Predictive Prognosis: Changing Role for the Pathologist

INTRODUCTION BREAST CANCER CARE

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

a ii The genetic code uses four different DNA bases. What is the maximum number of different DNA triplets that can be made using these four bases?

CANCER IMMUNOPATHOLOGY. Eryati Darwin Faculty of Medicine Andalas University

The mice were given these drugs each week during weeks 5 15 of the investigation.

Health Systems Adoption of Personalized Medicine: Promise and Obstacles. Scott Ramsey Fred Hutchinson Cancer Research Center Seattle, WA

FAQ-Protocol 3. BRCA mutation carrier guidelines Frequently asked questions

Data will be submitted to health authorities globally, including the US Food and Drug Administration (FDA) and European Medicines Agency (EMA)

Accelerate Your Research with Conversant Bio

PLENARY SESSION 1: CLINICAL TRIAL DESIGN IN AN ERA OF HORIZONTAL DRUG DEVELOPMENT Industry Perspective

How to carry out health technology appraisals and guidance. Learning from the Scottish experience Richard Clark, Principal Pharmaceutical

Media Release. Basel, 18 February 2017

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Technology Appraisals. Patient Access Scheme Submission Template

PCI Biotech press release 24 th August Attachment

Bringing the Fight to Cancer Annual Report

trial update clinical

EMEA experience with endpoints for Oncology drug approval

METASTATIC COLORECTAL CANCER: TUMOR MUTATIONAL ANALYSIS AND ITS IMPACT ON CHEMOTHERAPY SUMA SATTI, MD

Individual Study Table Referring to Part of the Dossier. Page:

Learning Objectives. ! At the end of the presentation,students will be able to:

FDA APPROVES AVASTIN FOR THE MOST COMMON TYPE OF KIDNEY CANCER

MOLOGEN AG. Pioneering Immune Therapy. Q1 Results 2014 Conference Call. Dr. Matthias Schroff, CEO

Media Release. Basel, 17 May 2018

Adjuvant Systemic Therapy in Early Stage Breast Cancer

My Personalized Breast Cancer Worksheet

For personal use only

So, Who are the appropriate individuals that should consider genetic counseling and genetic testing?

How to use market and clinical research together to develop claims

News Release. December 9, Not intended for UK-based media

Gynecologic Malignancies. Kristen D Starbuck 4/20/18

ANIMAL RESEARCH IS HELPING TO BEAT CANCER SOONER

Breast Cancer Basics. Clinical Oncology for Public Health Professionals. Ben Ho Park, MD, PhD

National Horizon Scanning Centre. Bevacizumab (Avastin) in combination with non-taxanes for metastatic breast cancer - first line therapy

Oncologia: dalla ricerca all applicazione clinica

CDx in oncology Prof. Christophe Le Tourneau, MD, PhD FEAM Geneva September 27, 2018

Targeted and immunotherapy in RCC

Erlotinib (Tarceva) for non small cell lung cancer advanced or metastatic maintenance monotherapy

Pertuzumab for the adjuvant treatment of HER2-positive breast cancer

Cabozantinib for medullary thyroid cancer. February 2012

Thoracic and head/neck oncology new developments

ADVANCES IN COLON CANCER

Cancer arises from the mutation of a normal gene. A factor which brings about a mutation is called a mutagen.

Highlights from the 2009 Annual Meeting of the American Society of Clinical Oncology. 20 Combination Treatments for Glioblastoma

Roche provides update on phase III study of TECENTRIQ (atezolizumab) in people with previously treated advanced bladder cancer

HEALTHCARE CLAIMS TRACKER A FOCUS ON ONCOLOGY CLAIMS. September 2018 For the period January 2017 December 2017

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

Copyright. Tocagen Inc. Lead Product Candidate: Toca 511 & Toca FC Preclinical Overview

National Horizon Scanning Centre. Bevacizumab (Avastin) for glioblastoma multiforme - relapsed. August 2008

HER2 status assessment in breast cancer. Marc van de Vijver Academic Medical Centre (AMC), Amsterdam

Introduction. Cancer Biology. Tumor-suppressor genes. Proto-oncogenes. DNA stability genes. Mechanisms of carcinogenesis.

Personalised Healthcare. will it deliver? Bob Holland Head of Personalised Healthcare & Biomarkers Innovative Medicines AstraZeneca R&D

Targeted Agents In Breast Cancer. Wonderful Music With New Instruments

Cancer Vaccines A novel approach to treat ovarian cancer ANZGOG (Australia and New Zealand Gynaecological Oncology Group) Meeting Feb 23-25, 2012

CHK1 Inhibitor. Prexasertib, LY MsOH H 2 O. Drug Discovery Platform: Cancer Cell Signaling

50 IN 10: Susan G. Komen's Bold Goal for Shaping History and Saving Lives. A Generation of Progress

PI3K/mTOR Dual Inhibitor

Media Release. Basel, 17 November 2012

Bringing the Fight to Cancer Annual Report

Gastric and Colon Cancer. Dr. Andres Wiernik 2017

Positioned for Growth

A world leader in allergy immunotherapy

Global Strategic Partners Merck and Pfizer Finalize Agreement to Co-Promote XALKORI (crizotinib)

FDA APPROVES HERCEPTIN FOR THE ADJUVANT TREATMENT OF HER2-POSITIVE NODE-POSITIVE BREAST CANCER

Year in review. Vit Perlik Director of Regulatory Science and Clinical Development

Patients Driving Progress

Cancer and Gene Alterations - 1

Table of contents. Page 2 of 40

Gastric Cancer Drug Discoveries

News Release. Merck and Pfizer Advance Clinical Development Program with Two Additional Phase III Trials of Avelumab.

1 Executive summary. Background

The basics of clinical trials

Breast Cancer. Excess Estrogen Exposure. Alcohol use + Pytoestrogens? Abortion. Infertility treatment?

Scottish Medicines Consortium

Overview of Cancer. Mylene Freires Advanced Nurse Practitioner, Haematology

(212) Investors Contact: Ryan Crowe (212)

Transcription:

What are Clinical Trials Clinical Trials are systematic studies designed to discover and verify the effects and/or adverse reactions of drugs (pharmacodynamics) and the absorption, distribution, metabolism and excretion of drugs (pharmacokenetics) in humans.

Why do we do Clinical Trials Laboratory experiments & discoveries Randomised Clinical Trials Safety & efficacy

CORU aims To improve the standards of care in NZ by participating in high quality clinical trials and provide innovative treatments To Improve our understanding of the development of cancer and it s clinical behaviour To contribute to advances in treatment

Background Drug discovery Synthesis and selection of appropriate formulation Pre clinical tests in the laboratory Clinical development Phase I, II, III Regulatory submission

Facts Drug development takes 10 15 years Cost approx $US 350 million - $US 1.8 billion Only 1 in 10,000 compounds make it to market Only 1 in 3 drugs recapture development costs

Types of Clinical Trials Treatment trials observational Interventional Randomised Prevention Trials Screening Trials Diagnostic Trials Quality of Life Trials Correlative Trials Early Access Trials

Phases of Clinical Trials Pre Clinical Research & Development involving laboratory and animal studies Determine physical and chemical characteristics Safety and Efficacy

Phase I Phases of Clinical Trials Small population 10-30 Healthy volunteers Short duration days to weeks Assess dosage, formulation & amount Pharmakokinetics & pharmacodynamics

Phase II Phases of Clinical Trials Enrol 30 100 Disease in question Weeks to month IIA dose range IIB response, safety, efficacy Drug Drug relationships, PK & PD

Phase III Phases of Clinical Trials Enrol 300 30,000 Confirm efficacy, complete safety, assess risks & benefits 2 pivotal trials plus special trials Drug interaction studies Effects on performance status Usually randomised and maty be placebo controlled

Phase IV Phases of Clinical Trials Post Marketing Surveillance Regulatory commitments Monitor efficacy in large population Identify problems including late & rare side effects Compare drugs with those of competitors Change formulations and dosages

Eligibility Clinical trial is open to all who meet the inclusion/exclusion criteria. Willing to consent South Island wide regardless of geographical location

Benefits of trial participation Access to new interventions Intervention being studied maybe more effective Regular & careful medical attention Results may help others Increased scientific knowledge

Changes over the years 1950 s Link between smoking & lung cancer Hormone s & cancer 5FU discovered 1960 s Prevention Scientists discover process of angiogenesis Hereditary link 1970 s First Oncogene discovered Simple mastectomy replaces radical mastectomy Tamoxifen as breast cancer prevention

Changes over the years Development of monoclonal antibodies 1980 s PSA screening Role of Dentritic cells for vaccines Taxol developed HER 2 overexpression in 15%-30% BC 1990 s VEGF discovered BRACA1 gene discovered Exercise found to reduce risk of cancer in post menopausal women

Changes over the years Irinotecan approved Testing os avastin begins Herceptin approved for use 2000 s Cox 2 inhibitors approved Monoclonal antibody Cetuximab slows cancer growth Vaccine developed to prevent cervical ca CEA test developed

Changing face of clinical trials Then. Treatment decisions based on tumour type Healthy cell damage & unwanted side effects Comparison of 1 cytotoxic or combination with another Few hormone only or chemo/rad trials Clinical trials less complicated Larger numbers recruited

Changing face of clinical trials Now.. New approaches with less side effects Immunotherapy Hormone therapy Targeted therapies Monoclonal Antibodies Kinase inhibitors Mutations and genetic marker Individual tumour testing

Changing face of clinical trials Case report forms electronic Data collection larger and more complex Investigations more complex Tumour evaluations more frequent Numbers involved in trials greater

Conclusion Science and technology are advancing at a rapid rate The direction of cancer research is changing Move from disease specific to individualised therapy Trials are becoming more complex and costly

Progress against cancer requires participation in clinical trials to carefully test the efficacy & safety of new treatments and to identify new avenues to prevent cancer, detect it early and increase survival and cure rates We depend on the willingness of our patients to take part in Clinical Trials